PCVX News and Press, Vaxcyte Inc. From 02/01/24

SAN CARLOS, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a firesi...

A look at the top 10 most actives in the United States Connexa Sports Technologies Inc. (CNXA) rose 101.2% to $0.4 on volume of 236,162,112 shares PROSHARES TRUST (SQQQ) rose 5.9% to $12.78 on volume of 177,226,563 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 4.5% to $5....

SAN CARLOS, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of co...

2024-01-30 16:20:57 ET More on Vaxcyte Vaxcyte: Looking Fully Valued Vaxcyte slips after pipeline updates Vaxcyte's pneumococcal shot shows safety profile comparable to Pfizer's Prevnar 20 Seeking Alpha’s Quant Rating on Vaxcyte Historical earn...

-- Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Phase 1/2 Study (n=1,015) Expected in Third Quarter of 2024 -- -- VAX-31 is Designed to Provide Coverage for Approximately 95% of IPD Circulating in the U.S. Adult Population -- -- Company’s ...

2024-01-21 06:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

-- Ms. Jones Joins Vaxcyte With Over 20 Years of Experience Leading People and Culture Strategies Across Multiple Industries -- SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccine...

2024-01-05 10:50:50 ET Shares of Vaxcyte ( NASDAQ: PCVX ) traded lower Friday after the biotech announced the latest updates from its clinical pipeline led by VAX-24, its vaccine candidate for the prevention of invasive pneumococcal disease. The biotech said that following a suc...

-- Company Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Phase 1/2 Study in Adults Following Independent Review of Phase 1 Safety and Tolerability Data; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following Succe...

2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...